Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron vs Observation in Stage III Melanoma
NCT00006249Phase 3Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2000
- Primary completion
- Aug 2003
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 18
01
Overview
A Phase 3 trial of peginterferon alfa-2b in melanoma, sponsored by European Organisation for Research and Treatment of Cancer. Status: unknown.
02
Drugs
peginterferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00006249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006249.